News

Aerie Pharmaceuticals completes enrollment of its Phase 2b clinical trial of AR-15512 (TRPM8 agonist) ophthalmic solution for the treatment of patients with dry eye disease

BY      |     April 30, 2021

Aerie Pharmaceuticals, an ophthalmic pharmaceutical company focused on the discovery and development of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced the completion of patient enrollment for COMET-1, a Phase 2b clinical trial of AR-15512 (TRPM8 Agonist) ophthalmic solution for the treatment of patients with dry eye disease.

 “With an estimated 30 million dry eye sufferers in the United States and less than 3 million treated, there remains a significant unmet need in the treatment of dry eye disease. When activated, the TRPM8 receptor may increase tear production, and its cooling sensation may lead to reduction in discomfort and ocular pain, a symptom of dry eye disease. We currently expect to report topline results for this trial in the third quarter of this year.”

More information about the clinical trial is available at www.clinicaltrials.gov under the study designation NCT04498182.

Read the press release here.

Read more about Aerie Pharmaceuticals here.



Photo by Perchek Industrie on Unsplash 


Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at [email protected]
Alternatively, you can leave your comments on LinkedIn or Twitter.